The Development of Pharmacoeconomy Guidelines in Indonesia

Ahmad Fuad Afdhal, Ph. D*
Presented at 7th ISPOR Asia-Pacific Conference
Singapore 3-6 September 2016
*Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia

BACKGROUND

- The introduction of Pharmacoeconomy course in one School of Pharmacy in Jakarta
- The establishment of ISPOR Indonesia Chapter
- The release of a textbook of Pharmacoeconomy in Bahasa Indonesia
- Seminar and workshop in Pharmacoeconomy

BACKGROUND [1]
The first printing of ISPOR Terminology book in Bahasa Indonesia
Master Program in Pharmacoeconomy
The increase in number of School of Pharmacy which has offered Pharmacoeconomy course

BACKGROUND (2)

Directorate General of Pharmaceutical Services and Medical Devices of the Ministry of Health of Republic of Indonesia on 15th September 2011 decided to appoint a team to design and construct the 1st Pharmacoeconomy Guidelines for Indonesia.
This PE Guidelines had been decided to be used for internal government institutions only.
METHODS

- Review all existing national pharmacoeconomy guidelines
- Excerpts of those pharmacoeconomy guidelines
- Make framework of pharmacoeconomy guidelines

DEVELOPMENT PROCESS

- Systematic of the content
- The content itself
- Panel Discussion for the content
- Resume of the panel discussion
PANEL DISCUSSION TEAM

- Senior consultants who are expert in pharmacoeconomy
- Officers from the Office of Ministry of Health
- Researchers from selected Universities
- Practitioners of government hospitals

CONTENT OF PE GUIDELINES (1)

- Theoretical review
- Perspective of Pharmacoeconomy evaluations
- Target users
- Comparisons
- Technique analyses
CONTENT OF PE GUIDELINES (2)

- Study design
- Strategy of implementation
- Implementation of Pharmacoeconomy techniques
- References

GOALS OF PE GUIDELINES

- Costs containment
- Optimize allocation of scarce healthcare resources
BENEFITS OF PE GUIDELINES

- Powerful marketing tool for targeting healthcare payers
- Improve patient access to cost-effective drugs

FUTURE DEVELOPMENT (1)

- In the near future PE Guidelines should be a path for a submission requirement for all pharmaceutical products.
PE Guidelines should be a requirement basis for pharmaceutical products reimbursement to Universal Health Coverage

FUTURE DEVELOPMENT (2)

- Therapeutic value
- Market price
- Clinical effectiveness
- Budget impact
- Cost-effectiveness from the perspective of Universal Health Coverage

CRITERIA FOR REIMBURSEMENT
OTHER IMPORTANT ASPECTS FOR PE GUIDELINES (1)

- Study design
- Calculation of costs
- Time horizon
- Valuation of outcomes

OTHER IMPORTANT ASPECTS FOR PE GUIDELINE (2)

- Modeling
- Handling uncertainty
- Discount rate
Thank you for your kind attention.